NCI-funded Companies in the Innovation Zone

If you are an investor or strategic partner looking to connect with oncology-focused startups, four NCI SBIR-funded companies will be attending and participating in the Innovation Zone. Check out more about these companies below and reach out to them through the partnering system or email Brittany Connors at brittany.connors@nih.gov.

• 7 Hills Pharma, LLC is a pharmaceutical company focused on developing immuno-modulatory drugs.
• Symberix is developing small-molecule inhibitors of GUS enzymes for use as adjunctive therapy to reduce the debilitating lower GI side effects of many existing FDA-approved oncology drugs.
• Synthis is developing a novel therapeutic, T3A, (T cell Targeted TGF-b Antagonist) to selectively eliminate TGF-b mediated immune suppression and restore tumor clearance.
• Theranano seeks to develop InCeRT (ImplaNts for ChemoRadiation Therapy), drug-eluting brachytherapy implants for Local Chemo-Radiation Therapy (LCRT), for the treatment of prostate and other cancers.